Endpoints News 23. März 2026 Apogee shares positive mid-stage maintenance data for eczema drug that could challenge Dupixent, Ebglyss
Endpoints News 23. März 2026 Arikayce could become Insmed’s second blockbuster following late-stage win in lung infection
Endpoints News 20. März 2026 Sarepta to ask FDA for full approval of exon skipping drugs; Rhythm's label expansion in rare form of obesity
Endpoints News 20. März 2026 China-rooted AI biotech Earendil Labs raises $787M ahead of possible IPO
Endpoints News 20. März 2026 UK’s NICE revisits Lilly, Eisai Alzheimer's drugs under new pricing threshold
Endpoints News 20. März 2026 Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
Endpoints News 20. März 2026 Idorsia looks for another CEO — again; Former Jazz exec makes a comeback
Endpoints News 20. März 2026 Genentech culls muscle-preserving drug in genetic diseases, raising questions about obesity trial
Endpoints News 20. März 2026 Turmoil at ACIP continues after claim committee ‘disbanded’ is quickly refuted